A single intraarticular injection of platelet-rich plasma seems beneficial to manage patients suffering from ankle osteoarthritis as it improves pain and physical function.

This prospective trial aimed to determine the safety and efficacy of a single intraarticular injection of platelet-rich plasma for individuals suffering from symptomatic ankle osteoarthritis. 

The study enrolled 44 individuals suffering from symptomatic ankle osteoarthritis for at least six months. Participants were given a single injection of platelet-rich plasma  (3 ml) into the affected ankles. Alteration in the visual analog scale (VAS) pain at six months from the baseline was the major endpoint. The secondary endpoints incorporated: (i) Single-leg stance test (SLS), (ii) American Orthopedic Foot and Ankle Society (AOFAS) hindfoot-ankle score, (iii) the Ankle Osteoarthritis Scale (AOS) score, (iv) rescue analgesics intake, and (v) patient satisfaction. In total, 39 participants (88.64%) fulfilled the trial.

The AOS and VAS substantially improved at one, three, and six-months. At one, three, and six months, the mean VAS pain considerably declined while the mean AOFAS hindfoot-ankle score improved from baseline (baseline VAS 4.1 ± 1.7, baseline mean AOFAS hindfoot-ankle score 80.3) The mean total AOS score reduced from baseline postinjection. At each follow-up, the SLS tests considerably improved. Acetaminophen intake dropped considerably and no severe adverse events were found to occur.

To manage ankle osteoarthritis patients, a single intraarticular injection of platelet-rich plasma may be used.